A Phase I, Open Label, Study To Evaluate The Safety And Immune Function Effects Of CP-675,206 In Combination With MART-1 Peptide-Pulsed Dendritic Cells In Patients With Advanced Melanoma
Phase of Trial: Phase I
Latest Information Update: 10 Sep 2015
At a glance
- Drugs Tremelimumab (Primary) ; Melanoma vaccine
- Indications Malignant melanoma
- Focus Adverse reactions
- 10 Jun 2017 Biomarkers information updated
- 10 Sep 2015 Retrospective analysis of this study and 3 other studies [See CTP700023738, CTP700001565 , study A3671001] were published in the European Journal of Cancer.
- 18 May 2010 Actual patient number added as 18 as reported by ClinicalTrials.gov.